 The investigational therapy in this trial, regulatory T cells Tregs, is evaluating an alternative to traditional immunosuppressive therapies for the treatment of systemic lupus erythematosus SLE, lupus. Too frequently, aggressive therapies are inadequate in the control of the disease and have potent side effects and complications. The collection and expansion of ones own T cells harnesses a naturally occurring regulatory mechanism to restore self-tolerance in people with lupus. Tregs are a specialized subset of T cells that function to control the immune response. Studies have shown that in active lupus, the numbers and function of Treg cells are significantly decreased, which contributes to an overactive immune system and an increase in disease activity. The hope is that these naturally occurring Treg cells can be used for the treatment of autoimmune diseases, including lupus. 